Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.Published in:2011By:Mita, A C;Papadopoulos, K;de Jonge, M J A;Schwartz, G;Verweij, J;Mita, M M;Ricart, A;Chu, Q S-C;Tolcher, A W;Wood, L;McCarthy, S;Hamilton, M;Iwata, K;Wacker, B;Witt, K;Rowinsky, E KPublication type:journal article
Key determinants of energy expenditure in cancer and implications for clinical practice.Published in:2016By:Purcell, S A;Elliott, S A;Baracos, V E;Chu, Q S C;Prado, C MPublication type:journal article